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Abstract
Background: PI3K and mTOR are key components of signal transduction pathways critical for cell survival.
Numerous PI3K inhibitors have entered clinical trials, while mTOR is the target of approved drugs for metastatic
renal cell carcinoma (RCC). We characterized expression of p85 and p110a PI3K subunits and mTOR in RCC
specimens and assessed pharmacologic co-targeting of these molecules in vitro.
Methods: We employed tissue microarrays containing 330 nephrectomy cases using a novel immunofluorescence-
based method of Automated Quantitative Analysis (AQUA) of in situ protein expression. In RCC cell lines we
assessed synergism between PI3K and mTOR inhibitors and activity of NVP-BEZ235, which co-targets PI3K and
mTOR.
Results: p85 expression was associated with high stage and grade (P < 0.0001 for both). High p85 and high mTOR
expression were strongly associated with decreased survival, and high p85 was independently prognostic on multi-
variable analysis. Strong co-expression of both PI3K subunits and mTOR was found in the human specimens. The
PI3K inhibitor LY294002 and rapamycin were highly synergistic in all six RCC cell lines studied. Similar synergism
was seen with all rapamycin concentrations used. NVP-BEZ235 inhibited RCC cell growth in vitro with IC50s in the
low hM range and resultant PARP cleavage.
Conclusions: High PI3K and mTOR expression in RCC defines populations with decreased survival, suggesting that
they are good drug targets in RCC. These targets tend to be co-expressed, and co-targeting these molecules is
synergistic. NVP-BEZ235 is active in RCC cells in vitro; suggesting that concurrent PI3K and mTOR targeting in RCC
warrants further investigation.
Background
Renal cell carcinoma (RCC) is among the ten leading
causes of cancer-related deaths, and the incidence has
been increasing by approximately 2% per year [1-4].
RCC is typically resistant to chemotherapy and radiation
therapy. The five-year survival rate is 90.8% for localized
RCC (confined to primary site), 63.3% for cases with
regional disease, and 11.1% in patients with distant
metastases [5]. The immunogenicity of RCC has been
the basis for use of cytokines such as interleukin-2 and
interferon for metastatic RCC, which benefit about 15%
of patients [6,7]. Alternative drugs are needed for
patients who are not responsive and/or are intolerant to
these therapies.
A growing understanding of the pathogenesis of RCC
has enabled us to identify factors pertinent to develop-
ment of RCC-targeting therapies. The discovery of VHL
tumor-suppressor gene inactivation and consequent
hypoxia-induced factor (HIF) activation of genes and
downstream pathways important to tumor progression,
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have provided the impetus for development of new
agents that target angiogenesis and proliferation path-
ways. Specifically, therapies that have demonstrated ben-
efit in metastatic RCC include the small molecule
tyrosine kinase inhibitors sunitinib, sorafenib and pazo-
panib [8-10], the anti-VEGF antibody bevacizumab [11],
temsirolimus and everolimus, inhibitors of mTOR,
which has been implicated in HIF transcription [12].
Although these new agents improve progression free
survival, none have shown a statistically significant
improvement in overall survival. In effect none are cura-
tive, and duration of response is often limited.
The PI3K pathway is activated and/or up-regulated in
cancers, and plays a critical role in tumor progression
[13,14]. There are three classes of PI3Ks; each has its
own substrate specificity [15,16]. Class IA PI3Ks, the
most widely implicated in cancer, primarily phosphory-
late phosphatidylinositol-4,5-bisphosphate to generate
the second messenger phosphatidylinositol-3,4,5-trispho-
sphate. This enzyme is a heterodimer consisting of a
p85 regulatory and a p110 catalytic subunit. Class IA
PI3K is activated by receptor tyrosine kinase (RTK) sig-
naling [17,18]. Binding of p85 to activated RTKs serves
both to recruit the p85-p110 heterodimer to the plasma
membrane, where its substrate phosphatidylinositol-4,5-
bisphosphate resides, and to relieve basal inhibition of
p110a by p85. Downstream mediators, including Akt
and PDK1, directly bind to phosphatidylinositol-3,4,5-
trisphosphate. Akt phosphorylates several cellular pro-
teins, including GSK3, GSK3ß, FOXO transcription fac-
tors, MDM2, and BAD, to facilitate cell survival and cell
cycle entry [15]. Akt phosphorylation also results in acti-
vation of the mTOR/raptor complex, which regulates
protein synthesis, cell growth, and proliferation [19].
There are two distinct functional mTOR complexes,
mTORC1 and mTORC2. mTORC1 (rapamycin sensi-
tive) consists of mTOR and Raptor, and its activation
results in phosphorylation of p70S6 and 4E-BP1.
mTORC2 consists of mTOR and the rapamycin-insensi-
tive companion of mTOR (Rictor), and causes Akt phos-
phorylation. Akt promotes protein synthesis and cell
growth by alleviating TSC1/2 suppression of mTOR,
allowing the latter to act as part of the mTOR-raptor
complex on 4EBP1 and S6 kinases.
Activation of the PI3K pathway in cancers has been
demonstrated in numerous studies. The two most com-
mon mutations are of p110a (PIK3CA) and loss of the
tumor suppressor PTEN. Amplification of PIK3CA and
Akt are occasionally observed in epithelial cancers [15].
Recently, high expression of the PI3K/p110g isoform
was implicated in pancreatic adenocarcinoma progres-
sion [20]. There is specific evidence of PI3K pathway
activation in RCC; it is constitutively activated in RCC
cells regardless of VHL status, and activation is tumor
specific [21]. Activation of mTOR can also up-regulate
HIF gene expression, which, in patients with VHL muta-
tions, can magnify HIF accumulation and expression of
HIF-inducible genes.
In RCC, data from moderate sized studies support
activation of the mTOR signaling pathway. Immunos-
tained tissue microarray sections of 150 RCCs showed
significantly higher expression of phosphorylated
p70S6K (p-p70S6K), phosphorylated-mTOR (p-mTOR)
and phosphorylated Akt (p-Akt) compared to normal
kidney, p < 0.05 [22]. Additionally, Robb et. al found
strong co-expression of phosphorylated-S6 (p-S6) and p-
mTOR in 14 of 29 clear cell carcinomas [23]. Signifi-
cantly decreased mean disease-free survival was
observed when caveolin was co-expressed p-AKT, p-
mTOR, p-S6 and phosphorylated-4EBP1 [24]. Therefore,
inhibition of mTOR has the potential to inhibit tumor
progression at multiple levels, and along with PI3K inhi-
bition is particularly attractive for development for RCC
treatment.
Despite the literature demonstrating the importance of
PI3K and mTOR in RCC pathogenesis, there is limited
information on total protein expression and co-expres-
sion in large cohort RCC tumor studies in the context
of patient survival. A previous meta-analysis of mRNA
expression microarrays revealed signature alternations in
the PI3K/AKT pathway that are associated with tumor
versus benign renal tissue [25]. Merseberger et. al deter-
mined expression patterns of PI3K, PTEN, p-Akt for
possible prognostic value in 176 RCC cases, and found
that activation of the PI3K pathway is associated with
adverse clinical outcome [26]. In a more recent study,
metastatic RCC samples from 132 patients and a subset
of 25 matched primary RCC specimens were stained for
PI3K, PTEN, p-Akt, p-mTOR, and p70S6. p-mTOR was
associated with decreased survival [27].
The relevance of the PI3K/Akt/mTOR signaling path-
way in RCC is the focus of ongoing research. Single-
agent mTOR inhibitors have some efficacy in RCC, and
co-targeting additional PI3K pathway members along
with mTOR might be a valuable strategy for overcoming
the escape mechanisms that can limit activity of mTOR
inhibitors. Seeing that PI3K inhibitors are currently in
clinical development, our purpose was to assess co-
expression of PI3K subunits, p110a and p85, and
mTOR in RCC tumors in a quantitative fashion and
study pharmacological co-inhibition of these targets in
vitro. To thoroughly assess co-expression of mTOR and
PI3K subunits in a quantitative fashion, we employed a
new method of automated, quantitative analysis
(AQUA) of in situ protein expression, which has been
validated and used in a number of previous studies
[28,29]. Expression of mTOR and PI3K, p85 and p110a
subunits was assessed in a large cohort of human
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specimens and we determined associations with stan-
dard clinical/pathological variables. We further studied
co-targeting these molecules in RCC cell lines, and
assessed the effects on cell growth and apoptosis using a
clinical quality compound, NVP-BEZ235.
Methods
Tissue Microarray (TMA) Construction
Briefly, representative regions were selected for coring
by pathologists based on the corresponding H&E-
stained full sections. The tissue microarray was con-
structed with single 0.6 mm-diameter cores of each case
spaced 0.8 mm apart in a grid format using a Tissue
Microarrayer (Beecher Instruments, Sun Prairie, WI).
The tissue microarray block was then cut into 5 μm sec-
tions with a microtome, adhered to the slide by an
adhesive tape-transfer method (Instrumedics, Inc., Hack-
ensack, NJ) and UV crosslinked. TMAs were con-
structed using RCC cores from 330 patients. Tumors
were represented by two cores from different areas of
the specimen. Specimens and clinical information were
collected with approval of a Yale University Institutional
Review Board. Histological subtypes included clear cell
(71%), papillary (14%), chromophobe (2%), mixed histol-
ogy (4%), oncocytomas (6%), and sarcomatoid tumors
(3%). Oncocytomas were excluded from survival ana-
lyses given that they have low metastatic potential and
are curable by nephrectomy. Eight percent had stage II
and III disease, 56% had stage I and 28% had stage IV
disease. 12% were Fuhrman nuclear grade I, 52% grade
II, 27% grade III and 9% grade IV. Specimens were
resected between 1987 and 1999; follow-up time was 2-
240 months (median-89.7). Age at diagnosis was 25-87
years (median-63). No patients were treated with suniti-
nib, sorafenib, pazopanib, bevacizumab, everolimus or
temsirolimus, although a few were previously treated
with interferon or interleukin-2 in the metastatic setting.
Performance status, LDH, hemoglobin and calcium
levels were unavailable.
Immunofluorescence
One set of two slides (each containing a core from dif-
ferent areas of tumor for each patient) was stained indi-
vidually for the three target markers, p85 and p110a
PI3K subunits, and mTOR. Antibody validation was
conducted by immunoblots to verify presence of a single
band of the appropriate size (not shown). AQUA stain-
ing was performed as described [30]. Slides were incu-
bated with mouse monoclonal anti-human PI3K p85,
(BD transduction Laboratories, Franklin Lakes, NJ) at
1:50, rabbit anti-human PI3K p110a, clone C73F8 (Cell
Signaling Technology, Danvers, MA) at 1:200 or rabbit
monoclonal anti-human mTOR, clone 7C10 at 1:40,
(Cell Signaling Technology). Goat anti-mouse (or anti-
rabbit) HRP-decorated polymer backbone (Envision,
Dako North America, Carpinteria, CA) was used as a
secondary reagent. To create a tumor mask, slides were
simultaneously incubated with rabbit (for p85) or mouse
(for p110a and mTOR) anti-cytokeratin (Dako) at 1:100,
and visualized with an appropriate secondary antibody
conjugated to Alexa 488 (Molecular Probes, Inc.,
Eugene, OR). The target antibody was visualized with
Cy5-tyramide (Perkin-Elmer, Boston, MA, and mounted
with ProLong Gold antifade reagent with 4, 6-diami-
dine-2-phenylindole (DAPI) (Invitrogen, Carlsbad, CA).
To verify that there was no background staining from
the Alexa 488, slides were stained with and without Cy5
tyramide.
Automated Image Acquisition and Analysis (AQUA)
Images were acquired and analyzed using extensively
described algorithms [30]. Briefly, monochromatic, high-
resolution (1024 × 1024 pixel) images were obtained of
each histospot. Tumor was distinguished from stroma
by cytokeratin/streptavidin signal. Cell surface coales-
cence of cytokeratin was used to localize membranes
and DAPI to identify nuclei. The target signal (p85,
p110a or mTOR) from the pixels within the cytoplasm
was normalized to area of tumor mask and scored on a
scale of 0-255 (the AQUA score). Histospots were
excluded if the tumor mask represented < 3% of the his-
tospot area.
Statistical Analysis
Statview and JMP 5.0 software were used (SAS Institute,
Cary, NC). AQUA scores for replicate tumor cores were
averaged. Prognostic significance of parameters was
assessed using the Cox proportional hazards model with
RCC-specific survival as an endpoint. Associations
between continuous AQUA scores of the target and
clinical and pathological parameters were assessed using
ANOVA. For demonstrating survival analyses, continu-
ous target AQUA scores were divided into quartiles and
survival curves were generated using the Kaplan-Meier
method, with significance evaluated using the Mantel-
Cox log-rank test.
Human Cell Lines
A498, ACHN, Caki-1, Caki-2, 769-P, and 786-0 cells
were obtained from American Type Culture Collection
and maintained per the supplier’s instructions (Mana-
ssas, VA).
Viability and Synergism Studies
At a density of 103, cells were plated in triplicate in 96
well plates with growth medium and allowed to
adhere overnight. The PI3K inhibitor, LY294002 (LC
Laboratories, Woburn MA), was used alone and in
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combination with the mTORC1 inhibitor, Rapamycin
(LC Laboratories), at 5-25 μmol/L and 0.02-0.5 μmol/
L, respectively for 48 hours. NVP-BEZ235 was studied
alone at concentrations of 10-500 hmol/L for 48
hours. The relative number of viable cells was
assessed by the luminometric Cell-Titer Glo assay
(Promega), and luminescent quantification was mea-
sured using a Viktor plate reader (Perkin Elmer).
Using CalcuSyn software (Biosoft, Ferguson, MO),
results were analyzed for synergistic, additive, or
antagonistic effects. Synergism is indicated by a Com-
bination Index (CI) of < 0.9, additivity by CI values of
0.9-1.1, and antagonism by CI > 1.1 [31]. To deter-
mine the IC50 for NVP-BEZ235, we used XLfit soft-
ware (IDBS, Surrey, UK).
Immunoblots
After treatment with NVP-BEZ235 at 100 hM for 1, 6
and 24 hours, cells were lysed using standard methods.
Primary rabbit anti-human antibodies were used: phos-
porylated AKT Ser-473, phosphorylated p70S6K Thr389
and phosphorylated pS6 Ser235/236 at 1:1000 (Cell Signal-
ing Technologies). To assess apoptosis, cells were trea-
ted with 100 hM, 500hM and 1000 hM NVP-BEZ235
for 72 hours. Levels of cleaved PARP (rabbit polyclonal
antibody, Cell Signaling) and cleaved caspase-2 (mouse
monoclonal antibody, BD Biosciences) were measured at
1:1000 for both. Mouse or rabbit anti-b-actin antibodies




To assess intra-tumor heterogeneity, two separate slides,
each containing a core from a different area of the
tumor for each patient, were used for each marker (p85,
p110a and mTOR). None of the markers had nuclear
staining, and only membranous/cytoplasmic compart-
ments were analyzed. By log-regression analysis, scores
for matching histospots were highly correlated (R = 0.7
for p85, R = 0.8 for p110a and R = 0.7 for mTOR).
Scores from the automated analysis are continuous from
0 to 255. The range of AQUA scores was 3.6-91.4 (med-
ian-32.3) for p85, 1.8-46.5 (median-7.9) for p110a and
4.1-75.5 (median-25.38) for mTOR. Examples of strong
AQUA staining for p85, p110a and mTOR are shown
in Figure 1A-C.
Scores from the two slides were combined for a single
dataset. Spots were deemed uninterpretable if they had
insufficient tumor, loss of tissue or abundant necrosis. A
composite score was formed by averaging the scores.
Patients with only one core were excluded from the ana-
lysis. The combined dataset had 264 cases for p85, 237
for p110a and 267 for mTOR.
We found a moderate correlation between expression
of the two PI3K subunits (r = 0.129, P = 0.046) and
stronger correlations between mTOR and the two PI3K
subunits; r = 0.251 for p85 and r = 0.385 for p110a (P
< 0.0001 for both). Expression of both PI3K sub-units
and mTOR was significantly higher in sarcomatoid
tumors (P = 0.002, P = 0.04 and P = 0.02, respectively),
and expression of p110a and mTOR was also signifi-
cantly higher in oncocytomas. Expression of mTOR was
also somewhat higher in papillary carcinomas (P = 0.02)
(Figure 2A). We found significant differences in p85
expression between early and late stage disease, and
expression of mTOR was higher in high grade tumors),
(Figure 2B), (P <0.0001 for all). p85 expression was
higher in cases with high Fuhrman grade (P < 0.0001)
(Figure 2B). No association was found between expres-
sion of p110a and stage or grade (Figure 2B).
AQUA provides continuous output scores rather than
divisions into “high” and “low” categories. We therefore
arbitrarily divided the continuous AQUA scores for the
three markers into quartiles. For p85 and mTOR, survi-
val of patients with AQUA scores in the top quartile
was significantly lower (Figure 2C). Using Cox univariate
analysis of continuous AQUA scores, high p85 PI3K
expression was strongly associated with decreased survi-
val (P < 0.0001). No association was found between con-
tinuous p110a scores and survival (P = 0.8287), while
continuous mTOR AQUA scores were associated with
decreased survival (P = 0.0099).
Using the Cox Proportional Hazards Model, we per-
formed multivariable analyses. Expression of p85
retained its independent prognostic value, as did stage
and Fuhrman grade (Table 1).
Synergism between PI3K and mTOR inhibition
Using 5, 25 and 50 μM of LY294002, we studied syner-
gism with a range of concentrations of rapamycin (20,
100 and 500hM). Synergism was seen in all six cell lines
at 5 μM LY294002 with all three concentrations of rapa-
mycin (Table 2). We note that the degree of viability
inhibition with all concentrations of rapamycin was
almost identical, as shown in Figure 3, using A498 and
Caki-2 cells as examples (p > 0.5 for comparison
between combinations of rapamycin and LY294002).
Viability of cells treated with LY294002, rapamycin or
the combination is calculated as a percent of the viabi-
lity of the untreated (control) cells.
Activity of the dual PI3K-mTOR inhibitor NVP-BEZ235 in
RCC cell lines
Given the synergism seen between the LY294002 and
rapamycin in RCC cell lines, we studied the in vitro
activity of NVP-BEZ235, which has been given to solid
tumor patients in phase I clinical trials. In all 6 RCC
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Figure 1 Automated, Quantitative Analysis (AQUA) of expression of p85, p110a and mTOR in renal cell carcinoma. AQUA uses
cytokeratin to create a tumor mask (two upper left quadrants at × 10). Cytokeratin staining was cytoplasmic and the mask is made by filling in
holes (lower left quadrants on left). 4’, 6-diamidino-2-phenylindole (DAPI) defines the nuclear compartment within the tumor mask, which is then
subtracted from the tumor mask to create a cytoplasmic compartment within the tumor mask. Target expression (A - p85, B - p110a and C -
mTOR) expression is measured within the cytoplasmic compartments, within the tumor mask (lower right quadrants), and each clinical case is
assigned a score based on pixel intensity per unit area within the tumor mask. Squares on right show × 40 magnification. in the tissue
microarray. The correlation with p110a was particularly strong.
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cell lines the IC50s of this compound were in the hM
range (Table 3).
NVP-BEZ235 target inhibition and induction of apoptosis
Targets of NVP-BEZ235, p-P70S6K, p-Akt and p-S6
were decreased in Caki-1, 769-P, A498 and 786-0 cells
with exposure to the drug. Cells were exposed to 0.1
and 1.0 μM NVP-BEZ235, or DMSO for 4 and 24
hours. b-actin is shown as a loading control. p-P70S6K
levels are undetectable at all concentrations and time
points studied, whereas levels of p-Akt and p-S6
decrease after 4 hours of drug exposure in a dose-
dependent fashion (Figure 4). Exposure of RCC cells to
Figure 2 Associations between marker expression and clinical/pathological variables. (A) Associations between target expression (p85,
p110a and mTOR) and histologic subtype. Expression of all three targets was higher in sarcomatoid tumors. (B) Associations between target
expression and tumor stage and Fuhrman grade. p85 and mTOR were associated with high grade and p85 with high stage. p110a levels were
not associated with stage or grade. (C) Kaplan-Meier survival curves of quartiles of AQUA scores for the three targets. High levels of both p85
and mTOR were associated with decreased survival.
Table 1 PI3K, p85 and p110 and mTOR Multivariate
Analysis*
Marker Relative 95% Confidence P-value
Risk Interval
PI3K - p85 1.026 [1.004 - 1.048] 0.02
PI3K - p110a 0.946 [0.872 - 1.025] 0.1762
mTOR 1.017 [0.992 - 1.042] 0.178
Stage 4.087 [2.120 - 5.469] < 0.0001
Nuclear Grade 2.898 [1.536 - 5.469] 0.001
*Statistically significant markers are bolded
Table 2 Combination indexes assessing synergism/
additivity/antagonism in rapamycin and LY294002








(nM) (nM) (CI) (CI) (CI) (CI) (CI) (CI)
5000 500 0.476 0.371 0.593 0.201 0.430 0.242
5000 100 0.461 0.193 0.492 0.212 0.444 0.262
5000 20 0.441 0.173 0.472 0.184 0.385 0.281
25000 500 1.388 0.678 1.409 1.270 1.356 0.830
25000 100 1.420 0.586 1.193 1.074 1.430 0.847
25000 20 1.393 0.484 1.227 1.020 1.530 0.910
Synergism is indicated by a CI of < 0.9, additivity by CI values between 0.9
and 1.1, and antagonism by CI of > 1.1.
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ascending concentrations of NVP-BEZ235 at 72 hours
resulted in PARP cleavage and cleavage of caspase-2
(Additional file 1, Figure 1). Caspase-2 was selected as it
has been shown in other publications to be activated in
response to treatment with NVP-BEZ235 [32,33].
Discussion
We studied expression patterns of PI3K pathway mem-
bers critical for cell survival and proliferation in a large
cohort of RCC specimens. We used a novel method of
quantitative immunofluorescence, AQUA. This method
is void of the pathologist-based bias associated with
DAB staining. The p85 subunit was associated with high
grade, high stage and decreased survival, and remained
an independent prognostic marker on multi-variable
analysis. p110a was not associated with high stage,
grade or survival. mTOR was associated with survival
on uni-variable analysis; however on multi-variable ana-
lysis it lost its independence as a prognostic marker.
The association between PI3K and mTOR and disease
progression suggests that they might be valuable drug
targets. The p85 subunit has both a regulatory and a sti-
mulatory role in activity of the PI3K pathway. The
p110a subunit is thought to be stimulatory only. The
functional roles of the subunits, in conjunction with our
findings of stronger co-expression of the p110a subunit
and mTOR, suggest that pharmacological co-targeting
of p110a and mTOR might be a useful strategy for
treating RCC.
Activation of the PI3K-Akt pathway and its role in
RCC progression was previously evaluated in a small
study of 48 patients with RCC by immunohistochemis-
try using an antibody to p-Akt, showing that p-Akt was
associated with high tumor grade and metastatic disease.
In addition, high p-Akt immunostaining was signifi-
cantly associated with decreased cancer-specific survival
[34]. Activation of the PI3K-Akt signaling pathway was
also examined in RCC cell lines treated with PI3K inhi-
bitors, wortmannin and LY294002 in previous studies
[21]. This study demonstrated that the PI3K-Akt signal-
ing pathway is constitutively activated in RCC cells,
regardless of VHL status, and that activation of this
pathway is tumor specific relative to corresponding nor-
mal renal tissue [21]. The same group conducted in vivo
Figure 3 Synergism between PI3K and mTOR inhibition. Cell viability assays in A498 (A) and Caki-2 cells (B): Cells were treated with
LY294002 alone, rapamycin alone (at three concentrations) or the combination of LY294002 and rapamycin. The combinations were highly
synergistic, with similar viability seen for all three concentrations of rapamycin used. There was no significant difference between the different
combination therapies (p > 0.5 for all).
Table 3 IC50 values of RCC cell lines treated with NVP-
BEZ235







In all 6 RCC cell lines the IC50s of NVP-BEZ235 were in the hM range.
Elfiky et al. Journal of Translational Medicine 2011, 9:133
http://www.translational-medicine.com/content/9/1/133
Page 7 of 10
studies of nude mice bearing human RCC xenografts
treated with LY294002. LY294002 inhibited tumor
growth, and p-Akt was reduced in these tumors [21].
The recognition that the PI3K pathway has gained as a
putative target in cancer therapy is reflected by the
recent increase in literature regarding novel PI3K inhibi-
tors [4,15,35-37]. Preliminary data from a phase I study
of the oral PI3K/mTOR inhibitor, NVP-BEZ235 was
conducted in patients with histologically confirmed,
advanced, unresectable solid tumors[38]. The findings in
the breast and colorectal patients which were reported
showed that NVP-BEZ235 was well tolerated with a
favorable safety profile.
There is also emerging evidence that mTOR activation
may play a role in promoting cell survival through the
activation of antiapoptotic proteins that contribute to
tumor progression. Given that the mTOR pathway is
deregulated in a number of cancers, it was anticipated
that mTOR inhibitors would have broad therapeutic
application across many tumor types. Two mTOR inhi-
bitors have been approved for use in metastatic RCC.
Both have clinical activity in this disease, however pri-
mary and acquired resistance limit their use, and our
studies suggest that the addition of a PI3K inhibitor
might result in improved outcome. While both wort-
mannin and LY294002 have provided tools to study
PI3K inhibition in pre-clinical models, the clinical use of
these compounds is limited due to their chemical prop-
erties, lack of specificity and poor tolerability [39-41].
Given the diversity of activity of PI3K family members,
isoform-selective inhibitors could potentially be better
tolerated [42]. Compounds that inhibit the p110a and
p85 subunits with a high degree of selectivity are in
development. Examples include the semi-synthetic viri-
din and wortmannin derivative PX-866 (Oncothyreon/
ProIX Pharmaceuticals) which has entered Phase I trials,
the LY294002 RGDS-conjugated pro-drug SF-1126
(Semafore Pharmaceuticals) which has entered Phase I/
II trials [43]. GDC-0941 (Genentech/Piramed/Roche) is
a Pan-class I PI3K inhibitor in Phase I trials. The Exe-
lexis compounds XL-147 and XL-765 are also in Phase I
trials.
In our models, activity of LY294002 alone in RCC cell
lines was limited, with IC50s in the micromolar range.
While this compound is also a weak inhibitor of mTOR,
there are a number of potential mechanisms of resis-
tance to PI3K inhibitors when administered alone. For
example, Akt can be activated by PI3K-independent
mechanisms such as mTORC2 activation [44]. Members
of the MAPK pathway have been shown to activate Akt
as well: ERK and RSK inhibit TSC2, which can result in
mTOR activation despite effective PI3K inhibition, as
reviewed [45]. Others have shown that inhibition of
PI3K results in down-regulation of S6K, a negative regu-
lator of PI3K through phosphorylation and inhibition of
insulin receptor substrate 1, causing a negative feedback
loop, as reviewed by Chalhoub and Baker [46]. One
potential method to overcome this resistance to pure
PI3K inhibition is co-inhibition of the down-stream
mediator, mTOR.
We found that the combination of LY294002 and
rapamycin was highly synergistic in all six RCC cell
lines studied. We used concentrations of rapamycin that
ranged from 20hM to 500hM. Similar inhibition of via-
bility was seen with all rapamycin concentrations used.
This is most important when designing novel therapies
and novel drug combinations, particularly as toxicity
associated with higher doses of mTOR inhibitors can be
quite remarkable [12]. Grade 3 adverse events occur in
a subset of patients treated with temsirolimus mono-
therapy and include hematologic toxicities, hyperlipide-
mia, hyperglycemia, asthenia and dyspnea. Similar
toxicities were seen in patients treated with everolimus
[47]. Moreover, combinations of mTOR inhibitors and
other targeted therapies have sometimes been surpris-
ingly toxic [48].
Figure 4 Effects of NVP-BEZ235 on renal cell carcinoma cells in vitro. Targets of NVP-BEZ235, p-P70S6K, p-Akt and p-S6 were decreased in
Caki-1, 769-P, A498 and 786-0 cells with exposure to the drug. Cells were exposed to 0.1 and 1.0 μM NVP-BEZ235, or DMSO (vehicle) for 4 and
24 hours. b-actin is shown as a loading control.
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Due to the poor pharmacologic properties of
LY294002, we further investigated the co-targeting of
PI3K and mTOR using a clinical-grade dual inhibitor,
NVP-BEZ235. Previously, significant toxicity in preclini-
cal models has been an issue in combined PI3K and
mTOR inhibitor studies. NVP-BEZ235 has an advanta-
geous pharmacologic profile and in vivo administration
results in high and sustained exposure in tumor tissue
[49]. It inhibits both mTORC1 and mTORC2, resulting
in enhanced inhibition of p-Akt compared to either
LY294002 or rapamycin, or the combination of
LY294002 and rapamycin, as shown in other malignan-
cies [50]. We found that this compound was highly active
in vitro, inhibiting RCC cell growth with IC50s in the low
hM range. Our studies further support results published
by Cho et. al demonstrating growth arrest in RCC cell
lines in vitro and in vivo using NVP-BEZ235 [51].
Conclusion
Expression of PI3K and mTOR is upregulated in aggres-
sive RCC tumor cells, suggesting that these are valuable
drug targets. Co-expression of the p110a subunit and
mTOR further indicate that co-targeting these molecules
in RCC might be a useful therapeutic approach. We
found that concurrent use of PI3K and mTOR targeting
drugs in RCC cell lines was synergistic in all cell lines
studied. The dual PI3K/mTOR inhibitor NVP-BEZ235
that is currently in clinical development is highly active
in RCC models, and further evaluation of this com-
pound in RCC is warranted.
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